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Abstract objectives To better inform local management of TB–diabetes collaborative activities, we aimed to
determine the prevalence of diabetes among persons with and without TB and to determine the
association between TB and diabetes in Kiribati, a Pacific Island nation.
methods We compared consecutively enrolled TB cases to a group of randomly selected community
controls without evidence of TB. Diabetes was diagnosed by HbA1c, and clinical and demographic
data were collected. A tuberculin skin test was administered to controls. The chi-square test was used
to assess significance in differences between cases and controls. We also calculated an odds ratio,
with 95% confidence intervals, for the odds of diabetes among cases relative to controls. Unweighted
multivariate logistic regression was performed to adjust for the effects of age and sex.
results A total of 275 TB cases and 499 controls were enrolled. The diabetes prevalence in cases
(101, 37%) was significantly greater than in controls (94, 19%) (adjusted odds ratio: 2.8; 95% CI
2.0–4.1). Fifty-five percent (108) of all diabetic diagnoses were new; this proportion was higher
among controls (64.8%) than cases (46.5%). Five patients with TB were screened to detect one
patient with diabetes.
conclusions There is a strong association between TB and diabetes in Kiribati and bidirectional
screening should be conducted in this setting.
keywords Tuberculosis, diabetes mellitus, Pacific, case–control study
Introduction
Tuberculosis (TB) rates vary considerably between Pacific
Island countries, ranging between 0 and 572 cases per
100 000 population [1]. Similarly, diabetes is common in
the Pacific, with between 7% and 38% of adults esti-
mated to have diabetes [2–8]; the prevalence of diabetes
in some Pacific Island countries is the highest in the
world [2]. The Republic of Kiribati – a Pacific Island
nation in the central Pacific – is burdened by both dis-
eases, has an estimated TB incidence of 429 per 100 000
population and an estimated prevalence of diabetes in
adults aged 25–64 years of 29% [1–3].
The association between TB and diabetes has been well
documented; a recent systematic review of 13 studies dem-
onstrated that diabetes is associated with a threefold risk
of progression from latent TB infection (LTBI) to TB dis-
ease [9]. People with TB and diabetes may be more likely
to die and have TB treatment failure or relapse than peo-
ple with TB who do not have diabetes [10]. Some studies
have also noted an association between diabetes and mul-
tidrug-resistant TB [11, 12], while others have not [10].
As the evidence about the association between TB and
diabetes has grown in the last few years, international
and regional policies now recommend screening patients
with TB for diabetes [13, 14]. In Kiribati, the national
TB programme (NTP) has not formally adopted this pol-
icy, but they have started to implement selective screening
of patients with TB for diabetes, in recognition of the
high rates of diabetes in the general population [3].
Although the topic has not been researched specifically,
clinicians from the Kiribati NTP also report that a sur-
prisingly large proportion of their patients with TB have
concurrent diabetes. They requested assistance conducting
research into this area to better inform policy about local
TB–diabetes collaborative activities. As many of the
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published studies on TB and diabetes have been con-
ducted outside of the Pacific or in countries with lower
burdens of TB and diabetes, Pacific TB programme man-
agers were also interested in local research conducted in
settings with a high dual burden of disease. Therefore,
we investigated the association between TB and diabetes
in Kiribati, to inform local and regional policy and prac-
tice on the integration of TB and diabetes care and man-
agement.
Methods
Study design
We used an unmatched case–control study design to
assess the relative odds of diabetes in residents of South
Tarawa, Kiribati, with TB to those without. Our study
adhered to STROBE guidelines for reporting the results
of case–control studies [15].
Setting
The Republic of Kiribati is a Pacific Island country con-
sisting of 32 coral atolls and one raised coral island
(Figure 1) [16]. This study was conducted in South
Tarawa, the island on which the capital is located, and
the location of the national referral hospital (Tungaru
Central Hospital), the National TB Control Centre
(TBCC) and the National TB Laboratory.
Participants
We estimated that to obtain a 95% confidence level with
a power of 80%, we would need a sample size of at least
187 cases (TB patients) and 187 controls (members of
the community without symptoms of TB). Eligible TB
cases were enrolled consecutively upon diagnosis between
June 2010 and March 2012. The following inclusion cri-
teria were used for cases: newly diagnosed patients with
TB over 18 years old, registered for treatment at the
TBCC, a resident of South Tarawa, not currently preg-
nant, and able to provide written informed consent.
Cases were all diagnosed by experienced TB physicians
using bacteriological, clinical and radiological criteria,
consistent with internationally accepted definitions rec-
ommended by WHO [17].
We attempted to enrol two cases for every control. We
identified our control group by first selecting enumeration
areas (EAs) of South Tarawa using probability propor-
tional to size sampling, where size was the number of
Figure 1 Map of the Republic of Kiribati showing its location in the Pacific Ocean (middle inset), and the study site; Tarawa (circled
in red and in left inset). Source: Secretariat of the Pacific Community.
2 © 2015 John Wiley & Sons Ltd
Tropical Medicine and International Health volume 00 no 00
K. Viney et al. TB and diabetes in Kiribati
households in the EA. We then identified 20 households
in each EA using a systematic skip process. Individual
controls over 18 years old were selected from identified
households based on a randomly distributed list of age
group and sex combinations, which was representative of
the general community, as described in the 2005 census
[18]. Trained nursing staff visited the selected households
to introduce the study and invite participation from one
control per household.
Controls were screened for TB disease by symptom
review [cough (duration > 2 weeks), fever, night sweats
and/or weight loss]. Any person with one or more of
these symptoms was deemed ineligible for the study and
was referred for further TB evaluation.
Controls were unmatched to cases and were enrolled
between August 2010 and December 2010. Other than
disease status, inclusion criteria for cases and controls
were identical.
Data collection
Trained nursing staff conducted the interviews of cases
and controls. Structured questionnaires were used to
record clinical and demographic information, including a
glycosylated haemoglobin (HbA1c) test result. Patients
with TB were enrolled as soon as practicable after their
diagnosis and were interviewed in the TB ward, the TB
clinic or at home. Controls were interviewed, had a
tuberculin skin test (TST) placed and had anthropometric
measurements taken at home.
Measurements and definitions
Height was measured in centimetres using a tape mea-
sure hung on a straight vertical surface. Weight, without
shoes, was measured in kilograms using lightweight digi-
tal scales. Waist circumference in centimetres was deter-
mined using the tape measure wrapped around the
waist at the level of the iliac crests latero-posteriorly
and immediately below the umbilicus anteriorly.
The HbA1c was measured using a portable point-of-
care HbA1c test (Bayer A1c Now: Metrika; Bayer
Healthcare LLC, Sunnyvale, CA, USA) [19]. This test
combines immunoassay and general chemistry [20] and
was chosen due to its portable nature, ease of operation,
acceptability to the population, minimally invasive
method and reported clinical accuracy [21]. For the pur-
poses of this study, any person with an HbA1c ≥6.5% or
any person who reported a diagnosis of diabetes and
treatment by a clinician was considered to have diabetes.
Any person with an HbA1c ≥6.5% was given brief infor-
mation about diabetes and was referred to the diabetes
clinic at Tungaru Central Hospital, for evaluation and
appropriate treatment.
After screening for active TB disease, a TST was used
to assess for LTBI among controls. Five tuberculin units
(0.1 ml) of purified protein derivative were injected intra-
dermally, and results were interpreted 48–72 h later by
measuring induration at the site of injection. An indura-
tion of 5 mm or more was considered positive for per-
sons with any immunosuppressive condition (such as
HIV or on immune suppressing medication), or persons
with recent exposure to someone with TB; otherwise an
induration of 10 mm or greater was considered positive.
We did not perform a TST on cases, or on controls who
reported a previous diagnosis of TB, or a history of a
previous positive TST.
Statistical analysis
Data were double-entered into EpiData version 3.1 and
were verified and corrected prior to analysis. All analyses
were carried out in EpiData Analysis version 2.2.2.178
(EpiData Association, Denmark). We calculated frequen-
cies for categorical variables and compared them using the
chi-square test; we calculated means and medians for con-
tinuous variables and compared them using the Student’s
t-test or the Wilcoxon test and Mann-Whitney U-test for
nonparametric data. P values <0.05 were considered signif-
icant. We calculated an odds ratio (OR), with 95% confi-
dence intervals (CIs), for the odds of diabetes among cases
relative to controls. Unweighted multivariate logistic
regression, adjusting for age and gender, was also per-
formed. Additionally, we estimated the proportion of TB
in South Tarawa attributable to diabetes as (Pe (OR–1)/
Pe(OR–1) + 1)*100, where Pe was the prevalence of diabe-
tes in the control group [22].
Ethical considerations
Ethical permission was obtained from the Institutional
Review Board at the United States Centers for Disease
Control and Prevention and the Human Research Ethics
Committee at the Australian National University, Austra-
lia. The Government of Kiribati does not have a human
research ethics committee, but the Ministry of Health and
Medical Services provided approval for the study. Written
and oral information was given to participants who pro-
vided written informed consent.
Results
A total of 499 controls (approximately 1% of the
population of the island) were recruited from the South
© 2015 John Wiley & Sons Ltd 3
Tropical Medicine and International Health volume 00 no 00
K. Viney et al. TB and diabetes in Kiribati
Tarawa community over the period August to December,
2010. Further, 275 TB cases were recruited from June,
2010 to March, 2012. No cases refused to participate in
the study, and the refusal rate in controls was <1%. The
clinical and demographic characteristics of cases and con-
trols are outlined in Table 1.
One hundred and one (37%) cases and 94 (19%) con-
trols were diabetic (P ≤ 0.001) (Table 2). Generally, the
proportion of study participants with diabetes increased
with advancing age, except in those >65 years. The pro-
portion of people with diabetes in all age groups was
consistently higher in cases than in controls, and the dif-
ference was statistically significant in three of the age
groups (35–44, 45–54, and ≥65 years). Overall, the odds
of diabetes were 2.8 times higher among TB cases than
controls (adjusted OR 2.8; 95% CI 2.0–4.1; adjusted for
age and sex). Cases were more likely than controls to
have an HbA1c ≥10% (64 vs. 36%, P < 0.001).
Among the 499 controls, 220 (44%) were current
smokers and 200 (40%) were obese (Body Mass
Index ≥ 30 kg/m2); among the 352 with TST data, 134
(38%) had evidence of LTBI, as evidenced by a positive
TST (Table 3). Of these, 62 (46%) were smokers and 28
(21%) had diabetes. Among the 64 diabetic controls with
TST data, 28 (44%) had evidence of LTBI; by compari-
son, 106 (37%) of 288 non-diabetic controls with TST
data had evidence of LTBI (OR 1.3; 95% CI 0.8–2.3).
A total of 87 persons from both the case and the con-
trol groups (11% of the study population) had previously
been diagnosed with diabetes (20% of the TB cases vs.
7% of the controls, P ≤ 0.001) Table 4. Another 108
people were diagnosed with diabetes as defined for this
study: 47 (17%) of the cases and 61 (12%) of the control
group (P < 0.01) Table 4. Fifty-five percent of persons
with diabetes were newly diagnosed as a result of the
study; five patients with TB and eight controls were
screened to detect one additional person with diabetes in
each group. The proportion of TB attributable to diabetes
was estimated to be 25%.
Discussion
This study is the first to document the association
between TB and diabetes in Kiribati. We found a high
prevalence of diabetes in our study population and a sig-
nificant association between diabetes and TB disease. The
data collected for controls provided the first information
on the prevalence of LTBI in the general community of
South Tarawa and provided updated information on the
prevalence of diabetes, obesity and smoking, which has
not been assessed since the last STEPwise approach to
surveillance (STEPS) survey in 2004–2006.
In this study, the prevalence of diabetes in the commu-
nity was lower than both the 28% prevalence cited in the
STEPS survey and a more recent estimate of 25% among
people aged 20–79 years [3, 23]; in the former, however,
diabetes was diagnosed by fasting plasma glucose [3].
Consistent with studies elsewhere, patients with TB in
Kiribati have nearly three times the odds of having diabe-
tes [9, 24, 25]. In our study, 37% of patients with TB
were identified as having diabetes. Prevalence estimates
of diabetes in patients with TB are dependent on many
factors, including the background prevalence of diabetes,
genetic predisposition and the screening and diagnostic
tests used to diagnose diabetes [26, 27]. Similar studies
have reported a range in the proportion of patients with
TB with diabetes from 9 to 44% [28–33]. In our study,
55% of the persons identified with diabetes were
previously undiagnosed. This large proportion of patients
newly identified with diabetes suggests that screening for
diabetes in the TB clinic is a worthwhile public health
intervention, provided that patients with diabetes can
access diabetes care. Further, the prevalence of
Table 1 Characteristics of 275 patients with TB and 499 com-
munity-based controls in Kiribati
Characteristic
Cases
(n = 275)
Controls
(n = 499) P-value
Age in years
mean (median)
37.5 (36) 37.7 (35) 0.54*
Female sex
(no. – %)
131 (48) 264 (53) 0.160
Mean % HbA1c 6.9 6.0 <0.001
HbA1c ≥ 10%
(no. – %)
45 (64) 25 (36) <0.001
Mean weight at
diagnosis
(kilograms)
64.9 79.2 0.001
Mean height
(centimetres)
166.2 164.1 0.006
Mean waist
circumference
(centimetres)
85.5 96.9 <0.001
Mean body mass
index (kg/m2)
22.3 29.5 <0.001
Self-reported
comorbidities†
(no. – %)
14 (5) 73 (15) <0.001
*Wilcoxon test and Mann-Whitney U-test for nonparametric data.
†These comorbidities included heart disease, asthma, hyperten-
sion, epilepsy, hepatitis, influenza, musculoskeletal pain, ulcers,
cancer, leprosy, arthritis and dyspepsia. The number represents
the number of patients who reported at least one comorbidity,
and not the number of comorbidities reported; participants were
able to report more than one comorbidity.
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undiagnosed diabetes in the controls (representative of
the general population) was higher than in the cases; this
may suggest that screening for diabetes in any healthcare
setting may have benefits and will detect people with pre-
viously undiagnosed diabetes. In this study, we advocate
screening patients with TB for diabetes as the patient is
engaged with the health system for 6 months or longer
(due to the duration of TB treatment) and this prolonged
contact with the health system may provide a good
opportunity for diagnosis and initial management of dia-
betes. In addition, the number of patients needed to
screen to detect one case of diabetes was five and was
lower than that of the general population, at eight.
The Collaborative Framework for the Care and Con-
trol of Tuberculosis and Diabetes recommends that
‘patients with TB should be screened for diabetes at the
start of TB treatment, where resources for diagnosis are
available’ [13]. The Pacific Islands Standards for the
Management of Tuberculosis and Diabetes outlines six
standards for managing patients with TB and diabetes.
Standard 1 states that ‘every person with TB over the age
of 18 should be screened for diabetes mellitus’ [14]. This
study, one of the few in the Pacific Islands to investigate
the association between TB and diabetes, supports those
recommendations.
Although we cannot say from this study if diabetes pre-
ceded TB, prospective evidence supports a causal rela-
tionship between diabetes and TB [34], and other studies
have rested on that assumption [35, 36]. Assuming that
diabetes preceded and was causally related to TB, we
estimate that 25% of TB in South Tarawa is attributable
to diabetes. Early identification and treatment of active
TB is a cornerstone of TB control and allows for
improved outcomes and decreased transmission of TB; as
such, patients with diabetes represent an important target
group for TB screening in Kiribati. Although our study
was a case–control study that does not provide direct evi-
dence of a causal link between TB and diabetes, the
association noted here and evidence from other cohort
and observational studies support the adoption of recent
recommendations to this effect [37–44].
Preventing the progression from LTBI to active disease
is another critical component of TB control [45]. In this
study, the prevalence of LTBI among controls was ele-
vated, at 38%. This is especially concerning given the
high prevalence of smoking and diabetes in this group,
both of which are potentially modifiable risk factors for
progression from LTBI to active disease [46].
Approximately half of diabetic controls in this study
had LTBI; therefore, only two diabetic patients would
need to be screened to identify one case of LTBI. Screen-
ing diabetic patients for LTBI would identify a group for
whom isoniazid preventive therapy could be a strategic
intervention for TB control. However, this is not yet rec-
ommended and further research is required in this area.
Limitations
There are important limitations to this study. We did not
have access to TB culture to verify all diagnoses of TB.
Importantly, we were not able to fully assess the temporal
relationship between TB and diabetes in patients with TB
and were, therefore, not able to determine the causal rela-
tionship between diabetes and TB. Moreover, we did not
test all patients with TB for diabetes at the same time after
their TB diagnosis. HbA1c measurements vary throughout
TB treatment and may be altered at the time of TB diagno-
sis due to inflammation, anorexia or the weight loss associ-
ated with TB, or during TB treatment by the effect of
medications including oral steroids and rifampicin [47].
Conclusions about causality implicit in the population
attributable fraction are based on other evidence [34], and
further research is needed to determine the optimal timing
for diabetes screening in patients with TB.
We assessed diabetes diagnosis using HbA1c from a
portable device. We did not validate diagnosis in all
individuals using another screening or diagnostic test.
Although HbA1c is now recommended for the diagnosis
Table 2 Prevalence of diabetes mellitus in 275 patients with TB and 499 community-based controls, by age group in Kiribati
Age group (years)
Cases (n = 275)
n (%)
Controls (n = 499)
n (%)
Odds ratio (95%
Confidence Interval) P-value
18–24 6/86 (7%) 7/128 (6%) 1.3 (0.4–4.0) 0.651
25–34 9/44 (20%) 14/115 (12%) 1.9 (0.7–4.7) 0.184
35–44 21/45 (47%) 24/105 (23%) 3.0 (1.4–6.2) 0.004
45–54 37/54 (69%) 23/77 (30%) 5.1 (2.4–10.9) <0.001
55–64 20/30 (67%) 20/43 (47%) 2.3 (0.9–6.1) 0.089
65 and over 8/16 (50%) 6/31 (20%) 4.2 (1.1–15.7) 0.030
Total* 101/275 (37%) 94/499 (19%) 2.5 (1.8–3.5) <0.001
*Age and sex-adjusted odds ratio: 2.8 (95% confidence interval 2.0–4.1).
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of diabetes in several settings, point-of-care tests are not
[48]. We compared agreement between the point-of-care
HbA1c test and HbA1c testing at a laboratory in a neigh-
bouring country for 15 persons not involved in the study,
and the mean difference between the two measurements
was 1%. The Pearson correlation coefficient was 0.76. It
is possible that we over- or underestimated the propor-
tion who are diabetic. The prevalence of diabetes that we
report among our control patients, however, is similar to
previous surveys, and our odds ratio was consistent with
other studies of TB and diabetes [9]. In addition, in
resource poor settings such as Kiribati, point-of-care tests
for diabetes represent an important, practical and proba-
bly cost-efficient method for testing patients at risk for
diabetes.
Other factors may influence HbA1c, such as chronic
anaemia and haemoglobinopathies [49]. We were not
able to check all participants for these conditions, and
surveillance for haemoglobinopathies is not well docu-
mented in Kiribati.
Lastly, control patients in this analysis were selected
using a cluster sampling scheme; we did not retain
sampling variables and were not able to weight the analy-
sis. It is possible that the precision of our CI around the
odds ratio is inappropriately narrow.
Conclusions
Diabetes and TB are strongly associated with Kiribati.
The high prevalence of LTBI, smoking and diabetes
presents a threat to, but also an opportunity for, TB con-
trol efforts. Screening for diabetes in the TB clinic will
likely increase the number of persons diagnosed with dia-
betes, and early diagnosis of diabetes should facilitate
better management of both conditions. In settings such as
Kiribati, with high TB case notification rates and a high
Table 4 Prevalence of previously known and newly identified
diabetes mellitus in 275 patients with TB and 499 community-
based controls, in Kiribati
Diabetes
Cases
(n = 275)
Controls
(n = 499) P-value
Previously known
diabetes
54 (19.6%) 33 (7.0%) <0.001
Newly identified
diabetes
47 (17.1%) 61 (12.0%) 0.006
Total with
diabetes
101 (36.7%) 94 (18.8%) <0.001
Proportion of total
diabetes newly
identified through
this study
46.5% 64.8% –
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prevalence of diabetes, screening persons with diabetes
for TB is also justified. The Ministry of Health and Medi-
cal Services should recommend that all patients with TB
be screened for diabetes and that the patients with diabe-
tes, at a minimum, be educated about the risks and signs
and symptoms of TB. We argue that collaboration
between national TB and diabetes programmes should be
strengthened, in much the same way that TB and HIV
collaborative activities have been implemented across a
range of settings.
Acknowledgements
We gratefully acknowledge the patients with TB and peo-
ple from the community who willingly participated in the
study, the study interviewers who interviewed the
patients with TB and community members, Dr Teatao Ti-
ira and Dr Kenneth Tabutoa (Kiribati Ministry of Health
and Medical Services; Dr Tabutoa is recently deceased),
and Dr Viliami Puloka (Healthy Pacific Lifestyle Team,
Secretariat of the Pacific Community) who supported the
implementation of the project, and the Global Fund to
Fight AIDS, TB and Malaria and the Australian Aid Pro-
gramme, Department of Foreign Affairs and Trade for
the financial support provided the study through a dedi-
cated operational research grant. We would like to dedi-
cate this study to Dr Kenneth Tabutoa (now deceased
and former Deputy Director of Public Health, Kiribati
Ministry of Health and Medical Services) for his tireless
work to manage and control TB in Kiribati. The findings
and conclusions in this report are those of the authors
and do not necessarily represent the official position of
the Centers for Disease Control and Prevention.
References
1. World Health Organization. Global Tuberculosis Report
2013. Geneva: World Health Organization, 2013.
2. International Diabetes Federation. International Diabetes
Atlas (6th edn), 2013. (Available from: http://www.idf.org/
diabetesatlas/download-book) (accessed 23 June 2014).
3. Kiribati Ministry of Health and Medical Services, World
Health Organization Western Pacific Region. Kiribati NCD
Risk Factors STEPS Report Tarawa, Kiribati: Kiribati Min-
istry of Health and Medical Services, World Health Organi-
zation, 2009.
4. Ministry of Health and Medical Services Solomon Islands,
World Health Organization. Solomon Islands NCD Risk
Factors STEPS Report. Suva: World Health Organization,
2010.
5. Ministry of Health Tokelau, World Health Organization.
Tokelau NCD Risk Factors STEPS Report. Suva: World
Health Organization, 2007.
6. Ministry of Health Fiji, World Health Organization. Fiji
Non-Communicable Diseases (NCD) STEPS Survey 2002.
Suva, Fiji: Ministry of Health Fiji, World Health Organiza-
tion, 2004.
7. Ministry of Health Republic of Marshall Islands, World
Health Organization. NCD Risk Factors STEPS Report
Ministry of Health, Republic of Marshall Islands. Suva:
World Health Organization, 2007.
8. Government of the Federated States of Micronesia, World
Health Organization. Federated States of Micronesia (Pohn-
pei) NCD Risk Factors STEPS Report. Suva: World Health
Organization, 2008.
9. Jeon C, Murray M. Diabetes mellitus increases the risk of
active tuberculosis: a systematic review of 13 observational
studies. PLoS Med 2008: 5: 1091–1101.
10. Baker M, Harries A, Jeon C et al. The impact of diabetes on
tuberculosis treatment outcomes: a systematic review. BMC
Med 2011: 9: 1–15.
11. Hsu A-H, Lee J-J, Chiang C-Y, Li Y-H, Chen L-K, Lin C-B.
Diabetes is associated with drug resistant tuberculosis in
eastern Taiwan. Int J Tuberc Lung Dis 2012: 7: 354–356.
12. Bashar M, Alcabes P, Rom W, Condos R. Increased inci-
dence of multidrug-resistant tuberculosis in diabetic patients
on the Bellevue Chest Service, 1987 to 1997. Chest 2001:
120: 1514–1519.
13. World Health Organization, International Union against
Tuberculosis and Lung Disease. Collaborative Framework
for the Care and Control of Tuberculosis and Diabetes Gen-
eva. Paris: World Health Organization International Union
against Tuberculosis and Lung Disease, 2011.
14. Pacific Island Tuberculosis Controller’s Association. Pacific
Standards for Management of TB and Diabetes. Pacific
Island TB Controller’s Association: Honolulu, United States
of America, 2013.
15. Vandenbroucke J, von Elm E, Altman D et al. Strengthening
the reporting of observational studies in epidemiology
(STROBE): explanation and elaboration. PLoS Med 2007:
4: 1628–1654.
16. Kiribati Office of the President. About Kiribati, (Available
from: http://www.climate.gov.ki/about-kiribati/) (accessed 2
Feb 2015).
17. World Health Organization. Treatment of Tuberculosis
Guidelines (4th edn), Geneva, Switzerland: World Health
Organization, 2010; 1–160.
18. Kiribati Ministry of Finance and Economic Development,
Secretariat of the Pacific Community. Census 2005 Report
Volume 2: Analytical Report. Noumea, New Caledonia:
Kiribati Ministry of Finance and Economic Development
Secretariat of the Pacific Community, 2007.
19. Bayer. BayerContour, 2013. (Available from: http://
www.bayercontour.com/Blood-Glucose-Monitoring/Classic
Meters/A1CNow?WT.mc_id=&WT.srch=1) (accessed 6
June 2013).
20. Bode B, Irvin B, Pierce J, Allen M, Clark A. Advances in
hemoglobin A1c point of care technology. J Diabetes Sci
Technol 2007: 1: 319–325.
© 2015 John Wiley & Sons Ltd 7
Tropical Medicine and International Health volume 00 no 00
K. Viney et al. TB and diabetes in Kiribati
21. Chang A, Frank J, Knaebel J, Fullam J, Pardo S, Simmons
D. Evaluation of an over-the-counter gylcated hemoglobin
(A1C) test kit. J Diabetes Sci Technol 2010: 4: 1495–1503.
22. Webb P, Bain C, Pirozzo S. Essential Epidemiology: An
Introduction for Students and Health Professionals. Cam-
bridge: Cambridge University Press, 2005.
23. International Diabetes Federation. Western Pacific 2011.
(Available from: http://www.idf.org/content/western-pacific)
(accessed 07 July 2011).
24. Alisjahbana B, Van Crevel R, Sahiratmadja E et al. Diabetes
mellitus is strongly associated with tuberculosis in Indonesia.
Int J Tuberc Lung Dis 2006: 10: 696–700.
25. Abdelmoez B, Abd-El-Nasser A, Baheeg M, Sedky A. Preva-
lence of tuberculosis among children who had type 1 diabe-
tes and were admitted to Elminia University Hospital.
Pediatrics 2008: 121(Suppl): S151.
26. Marais B, Lonnroth K, Lawn S et al. Tuberculosis comor-
bidity with communicable and non-communicable diseases:
integrating health services and control efforts. Lancet Infect
Dis 2013; 13: 436–448.
27. Chen R, Corona E, Sikora M et al. Type 2 diabetes risk
alleles demonstrate extreme directional differentiation
among human populations, compared to other diseases.
PLoS Genet 2012: 8: e1002621. doi:10.1371/journal.
pgen.1002621.
28. Restrepo B, Camerlin A, Rahbar M et al. Cross-sectional
assessment reveals high diabetes prevalence among newly-
diagnosed tuberculosis cases. Bull World Health Organ
2011: 89: 352–359.
29. Balakrishnan S, Vijayan S, Nair S et al. High diabetes preva-
lence among tuberculosis cases in Kerala, India. PLoS One
2012: 7: e46502. doi:10.1371/journal.pone.0046502
30. Vishwanathan V, Kumpatla S, Aravindalochanan V et al.
Prevalence of diabetes and pre-diabetes associated risk fac-
tors among tuberculosis patients in India. PLoS One 2012:
7: e41367. doi:10.1371/journal.pone.0041367.
31. Alladin B, Mack S, Singh A et al. Tuberculosis and diabetes
in Guyana. Int J Infect Dis 2011: 15: e818–e821.
32. Li L, Lin Y, Tan S et al. Screening of patients with tubercu-
losis for diabetes mellitus in China. Trop Med Int Health
2012: 17: 1294–1301.
33. Kibirige D, Ssekitoleko R, Mutebi E, Worodria W. Overt
diabetes mellitus among newly diagnosed Ugandan tubercu-
losis patients: a cross sectional study. BMC Infect Dis 2013:
13: 122. doi:10.1186/1471-2334-13-122.
34. Dooley K, Chaisson R. Tuberculosis and diabetes mellitus:
convergence of two epidemics. Lancet Infect Dis 2009: 9:
737–746.
35. Pablos-Mendez A, Blustein J, Knirsch C. The role of diabe-
tes mellitus in the higher prevalence of tuberculosis among
Hispanics. Am J Public Health 1997: 87: 574–579.
36. Faurholt-Jepsen D, Range N, PrayGod G et al. Diabetes is a
risk factor for pulmonary tuberculosis: a case-control study
from Mwanza, Tanzania. PLoS One 2011: 8: e24215.
doi:10.1371/journal.pone.0024215
37. World Health Organization. Systematic Screening for Active
Tuberculosis: Principles and Recommendations. Geneva:
World Health Organization, 2013; i–133.
38. Lin Y, Li L, Mi F et al. Screening patients with diabetes
mellitus for tuberculosis in China. Trop Med Int Health
2012: 17: 1302–1308.
39. Kermansaravi F, Metanat M, Sharifi-Mood B. Evaluation of
active pulmonary tuberculosis among patients with diabetes.
Int J Infect 2014: 1: e19632.
40. Amare H, Gelaw A, Anagaw B, Gelaw B. Smear positive
pulmonary tuberculosis among diabetic patients at the Des-
sie referral hospital, Northeast Ethiopia. Infect Dis Poverty
2013: 2. doi:10.1186/2049-9957-2-6.
41. Wang Q, Ma A, Han X et al. Prevalence of type 2 diabetes
among newly detected pulmonary tuberculosis patients in
China: a community based cohort study. PLoS One 2013:
8: e82660.
42. Prakash B, Ravish K, Prabhakar B et al. Tuberculosis-diabe-
tes mellitus bidirectional screening at a tertiary care centre,
South India. Pub Health Act 2013: 3(Suppl 1): 18–22.
43. India Diabetes Mellitus-Tuberculosis Study Group. Screening
of patients with diabetes mellitus for tuberculosis in India.
Trop Med Int Health 2013; 18: 646–654.
44. Jeon C, Harries A, Baker MA et al. Bi-directional screening
for tuberculosis and diabetes: a systematic review. Trop
Med Int Health 2010: 15: 1300–1314.
45. Lonnroth K, Corbett E, Golub J et al. Systematic screening
for active tuberculosis: rationale, definitions and key consid-
erations. Int J Tuberc Lung Dis 2013: 17: 289–298.
46. L€onnroth K, Jaramillo E, Williams B, Dye C, Raviglione M.
Drivers of tuberculosis epidemics: the role of risk factors
and social determinants. Soc Sci Med 2009: 68: 2240–2246.
47. Oluboyo P, Erasmus R. The significance of glucose intoler-
ance in pulmonary tuberculosis. Tubercle 1990: 71: 135–
138.
48. Committee TIE. International Expert Committee report on
the role of A1c assay in the diagnosis of diabetes. Diabetes
Care 2009: 32: 1327–1334.
49. Bonora E, Tuomilehto J. The pros and cons of diagnosing
diabetes with A1c. Diabetes Care 2011: 34(Suppl 2): S184–
S190.
Corresponding Author Kerri Viney, National Centre for Epidemiology and Population Health, Research School of Population
Health, Australian National University, Building 62, Cnr Mills and Eggleston Roads, Canberra ACT 0200, Australia.
E-mail: kerri.viney@hotmail.com
8 © 2015 John Wiley & Sons Ltd
Tropical Medicine and International Health volume 00 no 00
K. Viney et al. TB and diabetes in Kiribati
